Relay Therapeutics (RLAY) Net Margin (2021 - 2026)
Relay Therapeutics (RLAY) reported Net Margin of 2441.27% for Q1 2026, down 143780.0% year-over-year from N/an in Q1 2025, and down 211.16% quarter-over-quarter from 784.57% in Q4 2025.
Relay Therapeutics (RLAY) Net Margin (2021 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has 6 years of Net Margin data on file, last reported at 2441.27% in Q1 2026.
- Net Margin for Q1 2026 came in at 2441.27%, down 143780.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 2546.45% (up 179482.0% YoY), and the FY2025 annual result was 1795.53%, up 157933.0% from the prior year.
- Net Margin retreated to 2441.27% in Q1 2026 per RLAY's latest filing, from 784.57% in the prior quarter.
- Over five years, Net Margin peaked at 8349600.0% in Q4 2023 and troughed at 82765.55% in Q2 2023.
- A 5-year average of 624810.57% and a median of 10301.62% in 2025 frame the typical range for Net Margin.
- On a YoY basis, Net Margin climbed as much as 837627154 bps in 2023 and fell as far as 6172281 bps in 2023.
- A 5-year view of Net Margin shows it stood at 26671.54% in 2022, then jumped by 31405 bps to 8349600.0% in 2023, then plunged by 100 bps to 813.55% in 2024, then climbed by 4 bps to 784.57% in 2025, then slumped by 211 bps to 2441.27% in 2026.
- Business Quant data shows RLAY's Net Margin at 2441.27% in Q1 2026, 784.57% in Q4 2025, and 10301.62% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.82% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Relay Therapeutics | 2.86 Bn | 2.86 Bn | - | -2,441.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,441.27% |
| Dec 31, 2025 | -784.57% |
| Jun 30, 2025 | -10,301.62% |
| Mar 31, 2025 | -1,003.46% |
| Mar 31, 2024 | -813.55% |
| Dec 31, 2023 | 8,349,600.00% |
| Sep 30, 2023 | -260.82% |
| Jun 30, 2023 | -82,765.55% |
| Mar 31, 2023 | -41,698.67% |
| Dec 31, 2022 | -26,671.54% |
| Sep 30, 2022 | -24,470.64% |
| Jun 30, 2022 | -21,042.74% |
| Mar 31, 2022 | -14,808.11% |
| Dec 31, 2021 | -11,897.00% |
| Sep 30, 2021 | -9,134.08% |
| Jun 30, 2021 | -22,914.69% |
| Mar 31, 2021 | -4,431.09% |